ClinicalTrials.gg
CompletedNCT05661916Updated Feb 17, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

A Phase 1 interventional study of ALN-TTRSC04 and Placebo in Transthyretin-Mediated Amyloidosis, sponsored by Alnylam Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Amyloidosis by Alnylam Pharmaceuticals — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis · Alnylam Pharmaceuticals.

Enrollment
8th of 15
96 · median 96
Started
2023
the only one that year
Phase 1
5 of 22
none open now
Registered
18th of 22
by date

Among the 22 studies in Amyloidosis by Alnylam Pharmaceuticals, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 1, and was the 18th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

6 of the 22 studies in Amyloidosis by Alnylam Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Amyloidosis by Alnylam Pharmaceuticals, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.

03

Conditions studied

  • Transthyretin-Mediated Amyloidosis

Browse trials for

Keywords

  • ATTR amyloidosis
  • siRNA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening.

Exclusion criteria

Exclusion Criteria:

  • Has an estimated (eGFR) \<90 mL/min/1.73m\^2 at screening.
  • Has (ALT), aspartate aminotransferase (AST) or direct above the (ULN).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    ALN-TTRSC04

    Participants will be administered a single dose of ALN-TTRSC04.

    Drug: ALN-TTRSC04

  • Placebo comparator
    Placebo

    Participants will be administered a single dose of placebo.

    Drug: Placebo

Interventions

  • ALN-TTRSC04 will be administered by subcutaneous (SC) injection.

  • DrugPlacebo

    Placebo will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events

    Time frame: Up to 20 months

Secondary outcomes

  1. Change from Baseline in Serum Transthyretin (TTR) Levels Over Time

    Time frame: Up to 18 months

  2. Maximum Observed Plasma Concentration (Cmax) of ALN-TTRSC04

    Time frame: Day 1 up to Day 4

  3. Time to Maximum Observed Plasma Concentration (Tmax) of ALN-TTRSC04

    Time frame: Day 1 up to Day 4

  4. Area Under the Concentration-time Curve (AUC) of ALN-TTRSC04

    Time frame: Day 1 up to Day 4

  5. Fraction of ALN-TTRSC04 Excreted in the Urine (fe)

    Time frame: Up to Day 2

07

Study locations

1 site
  • Clinical Trial Site
    London, SE1 1YR, United Kingdom
08

References and documents

Publications

  • Badri P, Kolachana K, Duong A, Lasko M, Nandi T, Mehrotra N, Robbie GJ. Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules. Clin Pharmacokinet. 2026 Feb;65(2):293-311. doi: 10.1007/s40262-025-01606-0. Epub 2025 Dec 12. PubMed 41388232 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Sep 2025, 32 months.

Of 18 phase 1 interventional studies under Amyloidosis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 58. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Dec 22, 2022
StartActual
Jan 16, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05661916
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Jan 16, 2023
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Feb 17, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nucresiran

Start the discussion